First Time Loading...

Daxor Corp
NASDAQ:DXR

Watchlist Manager
Daxor Corp Logo
Daxor Corp
NASDAQ:DXR
Watchlist
Price: 8.57 USD -0.64%
Updated: Mar 28, 2024

Intrinsic Value

Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. [ Read More ]

The intrinsic value of one DXR stock under the Base Case scenario is 3.42 USD. Compared to the current market price of 8.57 USD, Daxor Corp is Overvalued by 60%.

Key Points:
DXR Intrinsic Value
Base Case
3.42 USD
Overvaluation 60%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Daxor Corp

Backtest DXR Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling DXR stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Daxor Corp's business.

What risks and challenges
does Daxor Corp face in the near future?

Summarize the latest earnings report
of Daxor Corp.

Provide P/E
for Daxor Corp and its competitors.

Financials

Balance Sheet Decomposition
Daxor Corp

Current Assets 25.9k
Receivables 25.9k
Non-Current Assets 34.8m
Long-Term Investments 34.8m
Current Liabilities 858.8k
Accounts Payable 103.1k
Short-Term Debt 755.7k
Efficiency

Earnings Waterfall
Daxor Corp

Revenue
163.4k USD
Cost of Revenue
-809.5k USD
Gross Profit
-646.1k USD
Operating Expenses
-239.5k USD
Operating Income
-885.6k USD
Other Expenses
1.2m USD
Net Income
280.6k USD

Free Cash Flow Analysis
Daxor Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

DXR Profitability Score
Profitability Due Diligence

Daxor Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

33/100
Profitability
Score

Daxor Corp's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

DXR Solvency Score
Solvency Due Diligence

Daxor Corp's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Long-Term Solvency
Low D/E
Short-Term Solvency
54/100
Solvency
Score

Daxor Corp's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DXR Price Targets Summary
Daxor Corp

Wall Street analysts forecast DXR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DXR is 24.48 USD with a low forecast of 24.24 USD and a high forecast of 25.2 USD.

Lowest
Price Target
24.24 USD
183% Upside
Average
Price Target
24.48 USD
186% Upside
Highest
Price Target
25.2 USD
194% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

DXR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

DXR Price
Daxor Corp

1M 1M
+15%
6M 6M
-10%
1Y 1Y
-14%
3Y 3Y
-30%
5Y 5Y
-27%
10Y 10Y
+7%
Annual Price Range
8.57
52w Low
7.19
52w High
13.03
Price Metrics
Average Annual Return -4.23%
Standard Deviation of Annual Returns 25.52%
Max Drawdown -70%
Shares Statistics
Market Capitalization 41.2m USD
Shares Outstanding 4 792 320
Percentage of Shares Shorted 0.36%

DXR Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Daxor Corp Logo
Daxor Corp

Country

United States of America

Industry

Health Care

Market Cap

41.2m USD

Dividend Yield

0%

Description

Daxor Corp. is a biotechnology company which develops and manufactures the BVA-100 blood volume analyzer, an instrument that measures human blood volume. The company is headquartered in New York City, New York. The Company’s investment objectives are capital preservation, maintaining returns on capital with a high degree of safety and generating income from dividends and option sales to help offset operating losses from the Company’s operating division. The firm intends to maintain a diversified securities portfolio comprised primarily of electric utility company common and preferred stocks. The firm seeks to maintain a minimum of 80% of its portfolio in equity securities of utility companies.

Contact

NEW YORK
New York City
350 5th Ave Ste 4740
+12123308500.0
http://www.daxor.com/

IPO

1983-07-25

Employees

-

Officers

Chairman, President & CEO
Mr. Michael Richard Feldschuh
Chief Scientific Officer & Director
Mr. Jonathan Adam Feldschuh
CFO, Chief Compliance Officer & Corporate Secretary
Mr. Robert J. Michel CPA, CPA, M.B.A.
Vice President of Development & Operations
Ms. Linda Cooper
Senior VP of Marketing & Commercial Development
Ms. Kathryn A. Kornafel
Vice President of Sales
Mr. Guido Manzo
Show More
Senior Vice President Commercialization & Customer Experience
Ms. Jean Oertel
Show Less

See Also

Discover More
What is the Intrinsic Value of one DXR stock?

The intrinsic value of one DXR stock under the Base Case scenario is 3.42 USD.

Is DXR stock undervalued or overvalued?

Compared to the current market price of 8.57 USD, Daxor Corp is Overvalued by 60%.